Aduro Biotech just inked a pharma deal with the Johnson & Johnson Innovation Center in California to help it develop its nascent lung cancer therapies.
Janssen Biotech, part of the Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ), will receive an exclusive, worldwide license to several of the cancer drugs in Aduro’s LADD immunotherapy platform
Aduro will receive a $30 million up front and as much as $817 million as it hits development, regulatory and commercialization milestones payments.
The company’s primary focus is experimental therapies using Listeria bacteria, which they genetically modify with disease-specific antigens. It had an earlier, existing partnership with Johnson & Johnson, but the larger company appears to be doubling down on the company as research evolves.
Aduro lauded the agreement as a major step forward for the tiny biotech.
For further deal information visit Current Agreements (subscription required)
Report: Partnering Deals and Alliances with Johnson & Johnson
Report: Top 50 Big Biotech Partnering and M&A Deal Trends
View: Partnering Scorecard in CP Insight– view top life science partnering deals by value
View: DealMetrics in CP Insight – the latest deal trend infographics for life science deal making
View: CP Insight’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: CP Insight’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity